What is KRAS G12C?
KRAS G12C is a specific mutation in the KRAS oncogene affecting approximately 13% of NSCLC patients. Until recently, KRAS mutations were considered impossible to target directly with drugs. The FDA approval of sotorasib (Lumakras) in 2021 and adagrasib (Krazati) in 2022 changed that paradigm, making KRAS G12C one of the most rapidly expanding trial landscapes in oncology.
KRAS G12C mutations are more common in smokers and former smokers with adenocarcinoma histology. Patients with KRAS-mutant tumors tend to have higher tumor mutation burden (TMB), which may influence immunotherapy trial eligibility.
Trial Landscape by Treatment Line
First-Line Treatment-Naive
Trials comparing sotorasib or adagrasib monotherapy vs. combination with chemotherapy vs. immunotherapy. Most focus on optimizing the initial strategy for best progression-free survival.
Post-Chemotherapy
KRAS G12C inhibitors are increasingly tested after chemotherapy failure. Trials explore switching to KRAS inhibitor monotherapy or combining with immunotherapy or other targeted agents.
Post-KRAS Inhibitor Progression
As more patients progress on sotorasib or adagrasib, trials testing next-generation KRAS inhibitors and resistance mechanisms are rapidly launching.
Combination Strategies
Growing trial portfolio combining KRAS G12C inhibitors with MEK inhibitors, immunotherapy, or EGFR inhibitors for patients with additional mutations.
KRAS G12C FAQs
Both are KRAS G12C inhibitors approved by the FDA, but they have different mechanisms and side effect profiles. Sotorasib covalently binds KRAS G12C, while adagrasib is reversible. Head-to-head trial data shows similar efficacy, but individual tolerability varies. Some trials are specific to one drug; verify eligibility carefully.
Post-sotorasib progression trials test: switching to adagrasib (if not previously treated), next-generation KRAS inhibitors, KRAS inhibitor + MEK inhibitor combinations, and KRAS inhibitor + immunotherapy. Liquid biopsy to identify acquired mutations (EGFR, TP53) may reveal which trials you qualify for.
Yes. Many trials test KRAS G12C inhibitors combined with PD-L1/PD-1 checkpoint inhibitors. KRAS-mutant tumors have higher TMB, which may predict immunotherapy benefit. Combination trials are increasingly available and often preferred over monotherapy.
(1) NGS report confirming KRAS G12C mutation. (2) Recent imaging (CT, PET scan). (3) Prior treatment history with dates and response. (4) Blood work and ECOG performance status from your oncologist. (5) For post-progression: molecular testing to identify acquired mutations.
Ready to find your matching KRAS G12C trials?
Upload your NGS report or pathology. We'll confirm your KRAS G12C mutation, match you to recruiting trials, and give you eligibility guidance for each one.